Servier signs third cancer drug discovery deal with Vernalis
This article was originally published in Scrip
Executive Summary
Servier has signed its third three-year oncology collaboration with UK-based Vernalis. All three deals focus on the discovery of different but unnamed targets using Vernalis's fragment and structure-based drug discovery platform.